APA (7th ed.) Citation

K, K., G, K., JS, B., BI, S., NA, B., U, R., . . . AD, K. (2026). Off-label use of alemtuzumab, belatacept, and rapamycin in kidney transplantation-Long-term real-world experience. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 26(1), 140. https://doi.org/10.1016/j.ajt.2025.09.004

Chicago Style (17th ed.) Citation

K, Krynychka, et al. "Off-label Use of Alemtuzumab, Belatacept, and Rapamycin in Kidney Transplantation-Long-term Real-world Experience." American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 26, no. 1 (2026): 140. https://doi.org/10.1016/j.ajt.2025.09.004.

MLA (9th ed.) Citation

K, Krynychka, et al. "Off-label Use of Alemtuzumab, Belatacept, and Rapamycin in Kidney Transplantation-Long-term Real-world Experience." American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, vol. 26, no. 1, 2026, p. 140, https://doi.org/10.1016/j.ajt.2025.09.004.